SCHEMBL75577

SCHEMBL75577

O=C1C(c2ccccn2)N(C2CC2)C(=O)N1C1C2CC3CC(C2)CC1C3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.39
EPHX2 P34913 1/20 0.39
GFER P55789 3/20 0.36
HSD11B1 P28845 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
SHMT2 P34897 1/20 0.34
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
CCKBR P32239 1/20 0.32
ALDH1A1 P00352 4/20 0.32
HPGD P15428 2/20 0.32
KDM4E B2RXH2 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27961125 0.65 FLT3 (0.45) FLT3SMN1; SMN2CYP1A2CYP2C19SHMT2
SCHEMBL77116 0.64 FLT3 (0.50) FLT3EPHX2HSD11B1SMN1; SMN2OPRM1
Bromide SCHEMBL28146019 0.64 FLT3 (0.44) FLT3SMN1; SMN2CYP1A2CYP2C19SHMT2
SCHEMBL4083794 0.64 DDB1 (0.40) FLT3HSD11B1SMN1; SMN2CYP1A2CYP2C19
SCHEMBL74972 0.63 EPHX2 (0.40) EPHX2HSD11B1CCKBRALDH1A1HPGD
SCHEMBL13187691 0.63 OPRM1 (0.43) GFERSMN1; SMN2OPRM1OPRD1OPRK1
SCHEMBL4083793 0.61 FLT3 (0.36) FLT3EPHX2HSD11B1ALDH1A1RAB9A
SCHEMBL22767893 0.61 OPRM1 (0.45) FLT3GFERSMN1; SMN2CYP1A2OPRM1
SCHEMBL5324640 0.60 EPHX2 (0.51) FLT3EPHX2HSD11B1CYP1A2OPRM1
SCHEMBL13558674 0.60 EPHX2 (0.51) FLT3EPHX2HSD11B1CYP1A2OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129423-B2 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; HOFFMAN-LA ROCHE INC. (US) 2012-03-06 US disclosed
EP-2308851-A1 Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
US-20080103183-A1 NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN-LA ROCHE INC. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103183-A1 NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HSD11B1, HSD17B1, HSD17B11 FLT3 2818/4885EPHX2 3757/4885GFER 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.